Bupropion and Cigarette-Related Cues in Smokers

University of California, Los Angeles (UCLA)

Status and phase: Completed; Phase 1

Conditions: Smoking, Tobacco; Smoking

Treatments: Drug: Bupropion; Other: Placebo

Study type: Interventional

Funder types: Other

Identifiers

NCT03920319

Brody011

Details and patient eligibility

About

Randomized, double-blind, before-after controlled trial to assess changes in regional brain activation in response to cigarette-related cues from before to after treatment with bupropion (vs placebo).

Enrollment: 34 patients

Sex: All

Ages: 18 to 65 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Treatment-seeking cigarette smoker
• Meet DSM-IV criteria for nicotine dependence
• Negative result on urine test for drug use during screening

Exclusion criteria

• History of any Axis I psychiatric diagnosis other than nicotine dependence
• Medical conditions that might affect brain function
• Current use of medications that could alter brain function
• Pregnancy
• Current illicit drug use other than occasional use of marijuana

Trial design

Primary purpose: Basic Science

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Double Blind

---

34 participants in 2 patient groups, including a placebo group

Bupropion

Experimental group

Description:

Participants assigned to 150mg of bupropion daily for the first 3 days, followed by titration up to 2 pills daily, separated by 8 hours, for the remaining 8 weeks of treatment.

Treatment:

Drug: Bupropion

Placebo

Placebo Comparator group

Description:

Participants assigned to pill placebo daily for the first 3 days, followed by titration up to 2 pills daily, separated by 8 hours, for the remaining 8 weeks of treatment.

Treatment:

Other: Placebo